Cargando…
State of the art in muscle glycogenoses
The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and...
Autor principal: | Angelini, C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore SpA
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040590/ https://www.ncbi.nlm.nih.gov/pubmed/21314016 |
Ejemplares similares
-
Progress and problems
in muscle glycogenoses
por: DiMauro, S., et al.
Publicado: (2011) -
Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)
por: Scalco, Renata S., et al.
Publicado: (2020) -
Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)
por: Pinós, Tomàs, et al.
Publicado: (2020) -
Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study
por: Rannou, Fabrice, et al.
Publicado: (2015) -
Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort
por: Piraud, Monique, et al.
Publicado: (2020)